Medtronic launches large-scale neurostimulation trial

Medtronic ($MDT) is looking to get its neurostimulation devices indicated for patients with failed back surgery syndrome, kicking off a global trial that will test to see whether the tech beats out drugs in patients with resulting lower back pain. Medtronic will enroll up to 300 patients at 30 centers in the U.S., Canada and Europe, and it's the first trial of its size to test surgical-lead-based neurostimulation on predominant lower back pain, the company said. The trial will also study the economic and quality of life factors related to the treatment, according to Medtronic. More

Suggested Articles

Sherlock Biosciences teamed up with Cepheid to help develop its CRISPR-based molecular diagnostic tech in oncology, infections and the coronavirus.

The spine surgery company ATEC has moved to acquire Paris-based EOS imaging, makers of FDA-cleared scanners and 3D orthopedic planning software.

Digital molecule designer Insilico Medicine has launched a new preclinical research program focused on treatments for brain cancer.